BioSpace News Archive

FogPharma today announced the first patient has been dosed in a first-in-human Phase 1/2 clinical trial of, FOG-001, the company’s first-in-class TCF-blocking β-catenin inhibitor.

Fulgent Genetics, Inc. today announced data from a Phase 1/1b clinical study of FID-007 in treating various solid tumors was presented in a poster session at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 3, 2023.

Amyris, Inc. announced that its Board of Directors has engaged the Business Recovery Services unit of PricewaterhouseCoopers and established a subcommittee of the Board, made up of three independent directors, working with Management, to execute on a transformation program to accelerate improvements to the Company’s cost and capital structure and liquidity.

Lucy Scientific Discovery Inc., a licensed producer of compounds for medicinal products, announced that it sent a proposal to Pasithea Therapeutics Corp., a biotechnology firm focused on innovative medical solutions, to acquire each share of its common stock.

On June 2nd, Daewoong Pharmaceutical (CEO Jeon Sengho, Lee Changjae) today announced that it and Neurogastrx have agreed to terminate the June 2021 license agreement, which granted Neurogastrx exclusive right to develop and commercialize Fexuprazan with respect to the U.S. and Canada market.

Servier today presented updated efficacy and safety data from the global Phase 3 AGILE study of TIBSOVO® (ivosidenib tablets) in combination with the chemotherapy azacitidine for newly-diagnosed acute myeloid leukemia (AML), and a new analysis of treatment response to TIBSOVO.

RLS, Inc., the third-largest nuclear medicine pharmacy network in the US, has been awarded a national group purchasing agreement for the distribution of Radiopharmaceutical Products with Premier, Inc, a leading healthcare improvement company headquartered in Charlotte, North Carolina.

Atara Biotherapeutics Presents Updated Tab-cel ® Clinical Effectiveness Data at ASCO 2023.

Daiichi Sankyo, Inc. and American Regent, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved INJECTAFER® (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure categorized as New York Heart Association class II/III to improve exercise capacity.

Enzolytics, Inc. provided updates regarding the sale of Virogentics, Inc. and Biogenysis, Inc. to Sagaliam Acquisition Corp and details of the recently released comprehensive study prepared by the Bulgarian Academy of Science for use by Korporativ Klinik Drug Research and Development as part of the continued development of the program to meet EMA requirements for clinical trials.